American Century Companies Inc. Sells 1,226,332 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

American Century Companies Inc. reduced its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 59.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 852,798 shares of the company’s stock after selling 1,226,332 shares during the quarter. American Century Companies Inc. owned about 0.40% of Hims & Hers Health worth $17,218,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HIMS. Arizona State Retirement System grew its position in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the last quarter. Belpointe Asset Management LLC increased its position in Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after buying an additional 1,205 shares during the period. Victory Capital Management Inc. increased its position in Hims & Hers Health by 6.6% during the 2nd quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after acquiring an additional 2,000 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. Jefferies Financial Group lifted their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler reiterated a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Bank of America lowered their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, September 13th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.86.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the transaction, the insider now directly owns 176,952 shares in the company, valued at approximately $2,919,708. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the completion of the transaction, the insider now owns 176,952 shares of the company’s stock, valued at $2,919,708. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $695,166.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 701,904 shares of company stock valued at $12,349,805. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Stock Down 3.8 %

NYSE:HIMS opened at $16.29 on Friday. The firm has a market capitalization of $3.50 billion, a PE ratio of -1,628.50 and a beta of 1.05. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The stock’s 50-day simple moving average is $17.35 and its 200 day simple moving average is $17.05.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm’s revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.